Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 2, Issue 5, 2009, Pages 291-297

  Rojas, Monica A ^a   Carlson, Noel G ^b   Miller, Thomas L ^b   Rose, John W ^b  

^a Salt Lake Veterans Affairs Healthcare System   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

clinical outcomes; interleukin 2 receptor alpha; long term daclizumab therapy; side effects

Indexed keywords

CORTICOSTEROID; DACLIZUMAB; INTERFERON; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DERMATITIS; DISABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; GRANULOMA ANNULARE; HUMAN; INFECTION; LIVER FUNCTION TEST; LYMPHADENOPATHY; MALE; MULTIPLE SCLEROSIS; PARESTHESIA; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SORE THROAT; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77953464476     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285609337992     Document Type: Article

References (25)

1. Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Walmann, T. et al. (2006) Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2 R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci 103: 5941-5946.
2. Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J. et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci 101: 8705-8708.
3. Brashir, K. and Whitacker, J. ( 2002) Current immunotherapy for demyelinating diseases. Arch Neurol 59: 726-731.
4. Buttman, M. and Rieckmann, P. ( 2008) Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 8: 433-455.
5. Composton, A. and Coles, A. ( 2008) Multiple sclerosis. Lancet 372: 1502-1517.
6. Engelhardt, B., Diamanstein, T. and Wekerle, H. ( 1989) Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis Rat. J Autoimmun 2: 61-73.
7. Hafler, D., Comston, A., Sawcer, S., Lander, S., Daly, M., de Jager, P. et al. (2007) Risk alleles for multiple sclerosis identified by a genomic study. N Engl J Med 357: 851-862.
8. Hayosh, N. and Swanborg, R. ( 1987) Autoimmune effector cells: IX Inhibtion of adoptive transfer of autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors. J Immunol 138: 3771-3775.
9. Kaufman, M.D., Wynn, D.R., Montalban, X., Wang, M. and Fong, A. ( 2008) A phase 2 randomized, double-blinded, placebo-controlled, multicenter study of subcutaneous daclizumab, a humanized anti-CD-25 monoclonal antibody, in patients with active, relapsing forms of multiple sclerosis - week 44 results. Neurology 70: PL01.003.
10. Linker, R.A., Kieseier, B.C. and Gold, R. ( 2008) Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 29: 558-565.
11. Lutterotti, A. and Martin, R. ( 2008) Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 7: 538-547.
12. Mehta, L. and Rose, J.W. (2009) Recurrent granuloma annulare during treatment with daclizumab. Mult Scler 15: 527-528.
13. Morris, J.C. and Waldmann, T. ( 2000) Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 59(Suppl. 1): i109-i114
14. Noseworthy, J. ( 2000) Multiple sclerosis. N Engl J Med 343: 938-952.
15. Nussenblatt, R.B., Fortin, E., Schiffman, R., Rizzo, L., Smith, J., van Veldhuisen, P. et al. (1999) Treatment of noninfectious intermediate and posterior uveitis with humanized anti-TAC mAb: A phase I / II clinical trial. Proc Natl Acad Sci 96: 7462-7466.
16. Nussenblatt, R.B., Peterson, J.S., Foster, C.S., Rao, N.A., See, R.F., Letko, E. et al. (2005) Initial evaluation of subcutaneous daclizumab treatment for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112: 764-770.
17. Rose, J., Lorberboum-Galski, H., Fitzgerald, D., Hill, K., Townsend, J. and Pastan, I. ( 1991) Chimeric cytotoxin IL2-PE40 inhibits EAE in the adoptive transfer model. J Neuroimmunology 32: 209-217.
18. Rose, J.W., Burns, J.B., Bjorklund, J., Klein, J., Watt, H.E. and Carlson, N.G. ( 2007) Daclizumab phase II trial in relapsing remitting multiple sclerosis: MRI and clinical results. Neurology 69: 785-789.
19. Rose, J.W., Foley, J.F. and Carlson, N.G. (2009) Monoclonal antibody treatment for multiple sclerosis. Curr Treatment Options Neurol 11: 211-220.
20. Rose, J.W., Watt, H.E., White, A.T. and Carlson, N.G. ( 2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56: 864-867.
21. Schippling, D.S. and Martin, R. ( 2008) Spotlight on anti-CD25: daclizumab in MS. Int Mult Scler J 15: 94-98.
22. Snyder, J.T., Shen, J., Azmi, H., Hou, J., Fowler, D.H. and Ragheb, J.A. ( 2007) Direct inhibition of CD40L expression contributes to clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood 109: 5399-5406.
23. Sospedra, M. and Martin, R. ( 2005) Immunology of multiple sclerosis. Ann Rev Immunol 23: 683-747.
24. Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P. et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338: 161-165.
25. Waldmann, T., Levy, R. and Coller, B. ( 2000) Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology 84: 394-406.